ArticleProceedings of the National Academy of Sciences of the United States of America2008
Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- The Coming of Age of Preclinical Models of MDS.Frontiers in oncology · 2022Pooled it
- 5-Azacytidine and decitabine induce C > G transversions in both murine and human cells.Leukemia · 2025Article
- Disruption of normal stem cell function and transmission of myelodysplastic syndrome by self-renewal of committed myeloid lineage cells.Stem cell reports · 2025Article
- The DNA Methyltransferase Inhibitor 5-Aza-4'-thio-2'-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development.Cancer research · 2024Article
- The bone marrow stroma in human myelodysplastic syndrome reveals alterations that regulate disease progression.Blood advances · 2023Article
- MutantCancer research · 2021Article
- Targeting miR-126 disrupts maintenance of myelodysplastic syndrome stem and progenitor cells.Clinical and translational medicine · 2021Article
- TLR2/6 signaling promotes the expansion of premalignant hematopoietic stem and progenitor cells in the NUP98-HOXD13 mouse model of MDS.Experimental hematology · 2020Article
- Identification of a metabolic gene panel to predict the prognosis of myelodysplastic syndrome.Journal of cellular and molecular medicine · 2020Article
- Thymic precursor cells generate acute myeloid leukemia in NUP98-PHF23/NUP98-HOXD13 double transgenic mice.Scientific reports · 2019Article
- Energy metabolism and drug response in myeloid leukaemic stem cells.British journal of haematology · 2019Review
- Article
- HoxA9 binds and represses the Cebpa +8 kb enhancer.PloS one · 2019Article
- Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome.Journal of visualized experiments : JoVE · 2018Article
- SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.Cell stem cell · 2018Article
- Article
- Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.Cancer research · 2017Article
- Somatic mutations in murine models of leukemia and lymphoma: Disease specificity and clinical relevance.Genes, chromosomes & cancer · 2017Article
- Article
- PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia.Cell death and differentiation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The myelodysplastic syndromes (MDS) comprise a group of premalignant hematologic disorders characterized by ineffective hematopoiesis, dysplasia, and transformation to acute myeloid leukemia (AML). Although it is well established that many malignancies can be transplanted, there is little evidence to demonstrate that a premalignant disease entity, such as MDS or colonic polyps, can be transplanted and subsequently undergo malignant transformation in vivo. Using mice that express a NUP98-HOXD13 (NHD13) transgene in hematopoietic tissues, we show that a MDS can be transplanted to WT recipients. Recipients of the MDS bone marrow displayed all of the critical features of MDS, including peripheral blood cytopenias, dysplasia, and transformation to AML. Even when transplanted with a 10-fold excess of WT cells, the NHD13 cells outcompeted the WT cells over a 38-week period. Limiting-dilution experiments demonstrated that the frequency of the cell that could transmit the disease was approximately 1/6,000-1/16,000 and that the MDS was also transferable to secondary recipients as a premalignant condition. Transformation to AML in primary transplant recipients was generally delayed (46-49 weeks after transplant); however, 6 of 10 secondary transplant recipients developed AML. These findings demonstrate that MDS originates in a transplantable, premalignant, long-term repopulating, MDS-initiating cell.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.